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Apolipoprotein E4 Genotype Increases the Risk of
Being Diagnosed With Posttraumatic Fibromyalgia
Jonathan C. Reeser, MD, PhD, Erin Payne, MPH, Terrie Kitchner,
Catherine A. McCarty, PhD, MPHObjective: To determine whether the apolipoprotein E4 (Apo E4) allele may be a genetic
risk factor for fibromyalgia syndrome (FMS).
Design: A retrospective assessment of associations between Apo E4 genotype and selected
environmental exposures among a cohort diagnosedwith FMS comparedwith control subjects.
Setting: Marshfield Clinic Research Foundation’s Personalized Medicine Research Project
PMRP) biobank.
articipants: One hundred fifty-one case subjects with fibromyalgia and 300 age- and
gender-matched control subjects.
Methods: Fibromyalgia case subjects were identified according to a strict phenotypic
definition from among the nearly 20,000 subjects enrolled in the PMRP. Age- and gender-
matched control subjects also were identified from the PMRP in a 2:1 control/case ratio. Apo
E4 genotype was determined by single nucleotide polymorphism analysis for both case
subjects with fibromyalgia and control subjects. Case subjects with fibromyalgia and control
subjects were asked to assess their level of function and stress by completing the Short
Form-36 and the Perceived Stress Scale.
Main Outcome Measures: Statistical associations between the Apo E4 genotype and
phenotypic criteria (diagnosis of FMS) as well as historical environmental exposures as
documented in the electronic medical record were assessed.
Results: Approximately one quarter of both case subjects with fibromyalgia and control
subjects were found to carry at least one Apo E4 allele. The odds ratio (OR) for case subjects
with fibromyalgia who had ever been in amotor vehicle accident and subsequently had been
diagnosed with FMS was increased among those with at least one copy of the Apo E4 allele
(OR 7.04) compared with those without an Apo E4 allele (OR 1.90). The presence of an Apo
E4 allele did not influence the degree of pain or level of function among those with FMS.
Conclusions: These data suggest that specific interactions between genetically susceptible
individuals (eg, those with at least one copy of the Apo E4 allele) and the environment (eg,
involvement in a motor vehicle accident) may contribute to the risk of being diagnosed with
FMS, although Apo E4 allele status does not appear to modulate perceived FMS severity.
PM R 2011;3:193-197
INTRODUCTION
The fibromyalgia syndrome (FMS) is a chronic pain condition that has been estimated to affect
2% to 6% of the U.S. population. More than 80% of those diagnosed with FMS are women.
Characteristic symptoms include diffuse (typically symmetric) soft-tissue pain, persistent fa-
tigue, headaches, cognitive ormemory impairment,morning stiffness, and nonrestorative sleep,
in addition to irritable bowel syndrome, irritable bladder, depression, and temporomandibular
joint discomfort. The diagnosis of FMS is determined solely by historical information and
physical examination findings. At present no “objective” diagnostic laboratory tests exist to
diagnose FMS; likewise, no universally effective treatments exist [1].
Despite its apparent prevalence, a residual undercurrent of skepticism exists in the broader
medical community regarding the validity of the fibromyalgia construct. This skepticism may
reflect our relatively rudimentaryunderstandingof thepathophysiologyunderlyingFMS. In that
regard, debate continues over whether FMS is a valid and unique clinical entity. FMS shares a
remarkable number of features with overtraining syndrome, chronic fatigue syndrome, and
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194 Reeser et al APO E4 INTERACTION INCREASES FIBROMYALGIA RISK(perhapsmost strikingly) postconcussive syndrome (PCS; Table
1) [2]. Although the shared features of these diagnoses are
eadily apparent, no clear-cutmechanistic basis for the similarity
etween these clinical conditions is immediately obvious.
PCS comprises a constellation of symptoms that occur on a
elatively common basis after mild traumatic brain injury [3,4].
ike FMS, PCS is characterized bymood disturbance, myalgias,
isordered sleep, cognitive impairment, and headaches. Risk
actors for PCS include female gender, age, and a history of
nciting trauma. Research has revealed that the apolipoprotein E4
Apo E4) genotype is associated with a poorer outcome from PCS
5]. In addition, Apo E4 may be thought of as a risk factor for the
evelopment of PCS because persons positive for Apo E4 have a
reater incidence of PCS after mild traumatic brain injury [6,7].
Evidence suggests that FMS is a neurophysiologic condition
nvolving a disordered perception of pain [8]. Environmental
riggers such as stress and trauma may play a critical role in the
evelopment of fibromyalgia, in addition to potentially modu-
ating the severity of symptoms experienced. The tendency for
he syndrome to cluster in families suggests that a genetic factor
ontributes to the risk of developingfibromyalgia [9,10].Arnold
t al [1] demonstrated that first-degree relatives of individuals
iagnosed with FMS were more likely to be diagnosed with
MS. However, it is evident that FMS does not follow a simple
endelian inheritance pattern; multiple genes probably con-
ribute to its etiopathogenesis. Although a unique genotype has
ot been definitively associated with FMS, genes that have been
mplicated in the diagnosis include those involved in serotonin
eurotransmission and neuropeptide synthesis [11].
Apo E is a polymorphic molecule found as a component of
any lipoproteins. In the central nervous system, Apo E is
roduced by astrocytes andmicroglia and has been proposed to
lay a role in transporting lipids from astrocytes to injured
eurons for repair. Apo E also is involved in synaptogenesis,
learance of degeneration products, microglial activation, and
aintenance of the cholinergic system [12]. Three known hu-
anApoE isoforms exist—E2,E3, andE4—that correspond to
Table 1. Comparison of clinical features of FMS and PCS
FMS PCS
Fatigue  
Headache  
IBS 
Impaired cognition  
Mood disturbance  
Morning stiffness  
Myalgias  
Sleep dysfunction  
TMJ 
Data compiled from Kato et al [2] and Johnston et al [3].
  Nearly universal complaint for this diagnosis.
  Very common complaint for this diagnosis.
  Occasional complaint for this diagnosis.
FMS  fibromyalgia syndrome; IBS  irritable bowel syndrome; PCS 
postconcussive syndrome; TMJ  temporomandibular joint discomfort.heir respective genes—Apo E 2, Apo E 3, and Apo E 4. Inight of the striking clinical similarities between FMS and PCS,
e concluded that it would be reasonable to investigatewhether
n association also exists between Apo E4 genotype and FMS.
his short report documents our findings, which suggest that
he Apo E4 allele, when combinedwith a history of having been
nvolved in a motor vehicle accident (MVA), is associated with
n increased risk of being diagnosed with posttraumatic FMS.
METHODS
Both the Research Committee and the Institutional Review
Board of the Marshfield Clinic approved the project. A total of
151 case subjects and 300 age- and gender-matched control
subjects were identified from within the Marshfield Clinic Re-
search Foundation’s Personalized Medicine Research Project
(PMRP) database. The PMRP is one of the United State’s largest
biobanks, with an enrollment of approximately 20,000 [13]. All
of the participants in the PMRP residewithin the catchment area
of theMarshfield Clinic (Figure 1), and the vast majority receive
their health care fromMarshfield Clinic (which has a searchable
electronic medical record [EMR]).
Potential subjects were identified by screening the EMR for
individuals who had received the diagnosis of FMS at least twice
during a 6-month period, then cross-referencing those identi-
fied cases with enrollment in the PMRP. Potential control sub-
jects were similarly identified, excluding individuals who had
ever received the diagnosis of FMS. Individual charts were
subsequently manually abstracted to confirm the participant’s
phenotype (ie, either case or control) using the following criteria:
● Case subjects were 18 years of age with documented
chronicwidespreadpain and tenderness.Most commonly the
diagnosing physician was a rheumatologist, physiatrist, or
family practitioner. Although the style and thoroughness of
symptom documentation varied, in every instance multiple
areas of pain were described, typically involving both sides of
the body. In addition, the EMR was reviewed to identify any
associated symptoms consistent with the diagnosis of FMS
Figure 1. The Personalized Medicine Research Project catch-
ment area.
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195PM&R Vol. 3, Iss. 3, 2011and to confirm that the potential subject had no history of
concomitant rheumatologic condition that might otherwise
explain their symptoms.
● Control subjects were 18 years of age with no diagnosis
of FMS or other rheumatologic disease (including discrete
myofascial pain).
The methods for separating cells and purifying and storing
eoxyribonucleic acid obtained from PMRP participants are
escribed elsewhere [14]. Genotyping analysis of the case and
ontrol subjects was performed with use of single nucleotide
olymorphism (SNP) primer extension/polymerase chain reac-
ion methodology. The SNPs used to determine the Apo E
enotype included rs7412 and rs429358.
Information regarding each subject’s documented history of
otor vehicular trauma, tobacco use, and bodymass index was
xtracted from the EMR. In addition, all subjects with FMS and
he associated control subjects were recontacted and invited to
rovide additional information regarding their current average
onthly pain (assessed by a 100-mm visual analogue scale
VAS]) and perceived stress levels (assessed by the 10-item
erceived Stress Scale [PSS]). Higher scores on the PSS indicate
reater levels of perceived stress [15]. The Short Form-36 (SF-
6) was administered as a means of assessing overall quality of
ife/perceived health status [16]. Eight composite scores and 2
ummary measures (each scored from 0 to 100, with higher
cores indicating a higher quality of life/health status) were
erived from the data collected from each respondent.
Statistics
Statistical analysis was performed according to the purposes of
the study with use of SPSS version 15.0 statistical software
(SPSS,Chicago, IL).2 Analyseswere performed to compare the
ategorical variables,whereas t-testswereused tocomparecontin-
ous variables. A P value.05 was interpreted as an indication of
tatistical significance. Multivariate analysis was performed to ex-
mine theassociationbetween theselectedpotential environmental
nd genetic risk factors and the FMS phenotype.
RESULTS
The PMRP FMS Cohort
We identified an experimental cohort from the PMRP biobank
consisting of 151 FMS case subjects and 300 age- and gender-
matched control subjects. The FMS case subjects ranged in age
from 20 to 80 years, with amean of 53.1 years. Control subjects
were age-matched within 5 years, with a range from 20 years to
81 years, and a mean of 52.7 years. Men comprised only 4% of
the case and control subjects within the cohort.We observed no
significant difference between the mean body mass index for
case and control subjects (31 and 29, respectively). The preva-
lence of various symptoms within the case group was calculated
to be as follows: diffuse myofascial pain, 100%; sleep disturbance,
97%; fatigue, 90%;headache, 87%;depression, 79%;paresthesias,65%; temporomandibular jointdiscomfort, 24%; irritablebowelor
bladder, 20%; and cognitive impairment, 18%.
Apo E4 Genotype
The percentage of the cohort found to carry at least one Apo E4
allele was 26.8%, although no significant difference existed
between the prevalence of the ApoE4 allele among case subjects
(26.0% had at least one allele) and control subjects (27.3% had
at least one allele). The percentage of FMS case subjects who
reported “ever smoking” was 41% compared with 24% of con-
trol subjects (P .001), but when stratified by Apo E4 status, a
history of ever smoking did not significantly affect the odds ratio
(OR) (OR 2.25 with no Apo E4 allele versus 2.29 for those with
1-2 copies; Table 2). We also evaluated the cohort for a docu-
mented history of MVA and found that 34% of those diagnosed
with FMS had ever been in an MVA compared with 14% of the
control group (P .001). Among those with a history of MVA,
he risk of being diagnosed with FMS was substantially greater
mong the subjects who carried at least one Apo E4 allele (OR
.04) compared with those without an Apo E4 allele (OR 1.90;
able2).Unfortunately, thenumberof case subjects carryingone-2
poE4alleleswhohadeversmokedandwhohadahistoryofMVA
as too small to permit computation of ameaningful OR.
Stress and Pain
Weexplored the role of stress andApoE4 genotype status in the
clinical manifestation of FMS by administering the SF-36 and
the 10-item PSS to the PMRP cohort. One hundred thirty-three
case subjects and 247 control subjects (88% and 82% response
rate, respectively) returned completed instruments. Respon-
dents also estimated their average monthly pain with use of a
100-mmVAS. As summarized in Table 3, those diagnosed with
FMS perceived greater stress, reported greater average monthly
pain, and had lower SF-36 Physical andMental Component Sum-
mary scores compared with control subjects. As expected, the
average pain score and the level of perceived stress were signifi-
cantly greater among those with FMS compared with control sub-
jects. However, Apo E4 status was not statistically associated with
Table 2. Multivariate associations between selected environ-
mental interactions, number of Apo E4 alleles, and the risk of
being diagnosed with FMS
No Apo E4 Alleles
Odds Ratio
(95% CI)
1-2 Apo E4 Alleles
Odds Ratio
(95% CI)
ver smoked 2.25 (1.33, 3.83) 2.29 (0.82, 6.33)
ver experienced
an MVA
1.90 (1.03, 3.54) 7.04 (1.98, 25.0)
po  apolipoprotein; CI  confidence interval; FMS  fibromyalgia
yndrome; MVA  motor vehicle accident.any of the outcomemeasures used to quantify stress or pain.
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PCS is a relatively common sequela of mild traumatic brain
injury, and research suggests that the Apo E4 genotype is asso-
ciated not only with an increased risk of developing PCS but
with a poorer outcome as well. Given the clinical similarities
between FMS and PCS, we wondered whether Apo E4 might
also be a genetic risk factor for FMS. In an attempt to answer that
question, we conducted this investigation by using the Marsh-
field Clinic’s PMRP biobank. Using strict phenotypic criteria to
define FMS, we identified a cohort of 151 subjects diagnosed
with FMS (case subjects) and another 300 age- and gender-
matched control subjects. Our results reveal a uniform distribu-
tion of the various Apo E alleles within the cohort, suggesting
that the Apo E4 allele is not an independent genetic risk factor
for FMS. However, when one considers the effect of a docu-
mented history of previous MVA, crosstab analysis reveals a
noticeable increase in the OR when Apo E4 allele status is
considered. These results suggest that an interaction occurring
between aspects of an individual’s history of selected environ-
mental exposures (eg, antecedentMVA) andApoE4 allele status
has the potential to influence their risk of being diagnosed with
posttraumatic FMS. Interestingly, althoughourdata suggest that
the Apo E4 genotype may enhance susceptibility to the devel-
opment of posttraumatic FMS, the data do not indicate that Apo
E4 influences the severity of the pain, the degree of stress, or the
quality of life experienced by individuals with FMS. No statisti-
cal association existed between monthly pain severity (as esti-
mated by the VAS) and the physical or mental component
summary scores of the SF-36 or the PSS and Apo E4 status.
Although carrying at least one copy of the Apo E4 allele may
therefore be a conditional risk factor for FMS, a person’s Apo E4
genotype does not appear to influence the severity of symptoms
experienced (as reflected by the outcome measures we chose to
use in this investigation). As discussed, previously published
research has identifiedApoE4 as a risk factor for PCS. Given the
clinical similarities between FMS and PCS, at the outset of this
inquiry we hypothesized that the 2 conditions may share com-
mon genetic risk factors. Indeed, our data suggest that Apo E4 is
a genetic risk factor for both PCS and FMS. However, there
appears to be a significant difference in the physiologic role
played by Apo E4 in the 2 conditions. Our observation that Apo
Table 3. Measures of stress and pain among the PMRP FMS c
Overall
Index Case Subjects Control Subjects Case Su
F-36 PCS 34 50 35
F-36 MCS 40 52 41
SS 20 15 20
AS 61 20 60
po  apolipoprotein; FMS  fibromyalgia syndrome; MCS  Mental Compo
edicine Research Project; PSS  Perceived Stress Scale score (higher sc
F-36 (higher scores are better); SF-36  Short-Form 36; VAS  visual anE4 does not seem to influence the severity of posttraumatic FMS Asuggests that the diagnosis is distinct fromPCS, at least in regard
to the genetic determinants of clinical outcome in general and
the role of Apo E4 in particular.
Eventually, genetic and proteomic research will permit us to
more fully understand and appreciate the similarities and differ-
ences in the pathophysiology underlying FMS and PCS, to say
nothing of other potentially related conditions such as chronic
fatigue syndrome or overtraining syndrome. Although we sus-
pect that the day will come when clinicians can obtain a battery
of laboratory tests to confirm the clinical diagnosis of FMS, at
this early stage we cannot recommend that Apo E4 genotyping
be incorporated into the workup of an individual with diffuse
myofascial pain of uncertain etiology.
The fibromyalgia cases identified in the cohort described
in this article were identified retrospectively from the Marsh-
field Clinic EMR. Because of the variability in documentation
we encountered, we could not use the American College of
Rheumatology criteria to verify the diagnosis of FMS. In
particular, had we insisted on written documentation of
myofascial pain at a minimum of 11 tender points above and
below the waist and on both sides of the body, we would not
have enrolled a sufficient number of cases to permit any
analysis of significance. Ultimately, however, we remain con-
fident that our cases do represent FMS because they had each
been given the International Classification of Diseases, 9th revi-
sion diagnosis of FMS twice within 6 months, they were
documented as having widespread myofascial pain, and the
collective frequency of associated symptoms was generally
consistent with that documented in the literature.
Having demonstrated the utility of the PMRP biobank and
the associated EMR in conducting this type of analysis, we
propose that additional research be conducted in an effort to
identify additional risk factors for and interesting genotypic
associations with FMS. In fact, the entire PMRP biobank was
recently “fingerprinted” with a panel of 30 medically relevant
SNPs [14]. Four SNPs were shown to have a significant statisti-
cal association with the FMS phenotype (Table 4). The matrix
metallopeptidase 1 allele (MMP1) demonstrated the strongest
association (28.819,P .012). TheMMP1 allele previously
as been associated with endometriosis and rheumatoid arthri-
is. Comparison of the frequency distribution of MMP1 and the
o E4 Alleles 1-2 Apo E4 Alleles
Control Subjects Case Subjects Control Subjects
50 33 51
52 38 53
15 21 15
21 62 19
mmary score of the SF-36 (higher scores are better); PMRP  Personalized
ggest greater stress); PCS  Physical Component Summary score of the
scale score (higher scores indicate greater average monthly pain).ohort
No Ap
bjects
nent SupoE4genotypeswithin theFMScohort revealed that FMScase
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carry at least one copy of the Apo E4 allele, whereas control
subjects were more likely to be homozygous for MMP1 (or
/) and have 1-2 copies of the Apo E4 allele (P  .002,
ikelihood ratio 9.188). Determination of the physiologic signif-
cance of an interaction between the Apo E4 and MMP1 alleles
or any of the other SNPs identified in Table 4) must await
urther analysis, as must determination of whether any of these
NPs can be demonstrated to have an association with PCS or
ther clinically similar pain syndromes.
CONCLUSION
Our data suggest that Apo E4 may be a conditional genetic risk
factor for FMS in that there appears to be an interaction between
individualswith at least oneApoE4 allele and a history ofmotor
vehicular trauma that increases the risk of being diagnosed with
FMS. Interestingly, Apo E4 does not seem to play a significant
role in the degree to which individuals with posttraumatic
fibromyalgia experience pain or perceive stress. Replicating this
investigation in a larger population should confirm the signifi-
cance of the preliminary findings reported here and also permit
additional insight into the genetic basis of how conditions that
are clinically similar differ from one another.
ACKNOWLEDGMENTS
Marie Fleisner of the Marshfield Clinic Research Foundation
provided assistance in formatting and preparing our final
manuscript for submission.
Table 4. Additional SNPs associated with FMS
Allele SNP
Observed
Association 2 Value
MP1 delG rs1799750 Case subjects 58% –/C 8.82
TR2A CC rs6313 Control subjects 56%
CT or TT
7.41
ELAC2 rs4792311 Case subjects 2
more likely AA
7.39
CBS AA rs234706 Case subjects 2
more likely AA
8.49
A  adenine; C  cytidine; CBS  cystathionine-beta-synthase; del  deleted;
LAC2  elaC homolog 2; FMS  fibromyalgia syndrome; HTR2A  5
ydroxytryptamine receptor 2A; MMP1 delG  matrix metallopeptidase 1de-
eted G; SNP  single nucleotide polymorphism; T  thymidine.
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